natgillin/translations-raw huggingface dataset:
Et fem-årigt langtidsopfølgende observationsstudie indrullerede 97 pædiatriske patienter med kronisk hepatitis-C efter behandling i to af de tidligere nævnte multicenterstudier. 
A five-year long-term, observational, follow-up study enrolled 97 paediatric chronic hepatitis C patients after treatment in two previously mentioned multicentre trials.
Enhver patient med manglende resultater i og efter perioden omkring opfølgningsuge 12 blev betragtet som en non-responder ved 24 ugers opfølgning. 
Any subject with missing data in and after the follow-up week 12 window was considered to be a non-responder at week 24 of follow-up.
- Teratogenicitet: Betydeligt teratogent og/eller embryocidt potentiale er vist for Rebetol i alle dyrearter, i hvilke tilstrækkelige undersøgelser er blevet udført, og forekommer ved så lave doser som en tyvendedel af den anbefalede humane dosis (se pkt. 
- Teratogenicity: Significant teratogenic and/or embryocidal potential have been demonstrated for Rebetol in all animal species in which adequate studies have been conducted, occurring at doses as low as one twentieth of the recommended human dose (see section 5.3).
Hos børn og unge patienter behandlet med Rebetol plus interferon alfa-2b reduceres Rebetol-dosis til 7,5 mg/kg/dag. 
In children and adolescent patients treated with Rebetol plus interferon alfa-2b, reduce Rebetol dose to 7.5 mg/kg/day.
Enogfyrre procent af forsøgspersonerne (97/235) havde plasma HCV-RNA niveauer under detektionsgrænsen ved behandlingens uge 4 og uge 24. 
Forty-one percent of subjects (97/235) had nondetectable plasma HCV-RNA levels at week 4 and week 24 of therapy.
Orale former for Rebetol monoterapi er blevet undersøgt til behandling af kronisk hepatitis C i flere kliniske undersøgelser. 
Oral formulations of Rebetol monotherapy have been investigated as therapy for chronic hepatitis C in several clinical trials.
På grund af væsentlige stigninger i plasmakoncentrationen af ribavirin hos patienter med moderat og svært nedsat nyrefunktion anbefales dosisjustering af Rebetol hos voksne patienter med kreatininclearance < 50 ml/min. 
Due to substantial increases in ribavirin plasma concentrations in patients with moderate and severe renal impairment, Rebetol dose adjustments are recommended in adult patients with creatinine clearance < 50 mL/minute.
Non-responders som tidligere havde fået behandling med pegyleret interferon alfa/ribavirin, var mindre tilbøjelige til at respondere i 12. uge på genbehandling end non-responders på ikke pegyleret interferon alfa/ribavirin (12,4 % versus 28,6 %). 
Non-responders to prior therapy with pegylated interferon alpha/ribavirin were less likely to achieve a week 12 response to retreatment than non-responders to non-pegylated interferon alpha/ribavirin (12.4 % vs. 28.6 %).
Mulige patienter til disse undersøgelser havde kronisk hepatitis C bekræftet ved en positiv HCV-RNA polymerase kædereaktionstest (PCR) (> 30 IE/ml), en leverbiopsi i overensstemmelse med en histologisk diagnose med kronisk hepatitis uden anden årsag til den kroniske hepatitis, samt en abnorm serum ALAT. 
Eligible patients for these trials had chronic hepatitis C confirmed by a positive HCV-RNA polymerase chain reaction assay (PCR) (> 30 IU/mL), a liver biopsy consistent with a histological diagnosis of chronic hepatitis with no other cause for the chronic hepatitis, and abnormal serum ALT.
På grund af risikoen for bivirkninger hos de ammede børn skal amning ophøre, før behandling påbegyndes. 
Because of the potential for adverse reactions in breast-fed infants, breast-feeding must be discontinued prior to initiation of treatment.
I den pivotale kliniske undersøgelse af effekt blev patienterne instrueret i at indtage ribavirin til et måltid for at opnå maksimal plasmakoncentration af ribavirin. 
In the pivotal clinical efficacy trial, patients were instructed to take ribavirin with food to achieve the maximal plasma concentration of ribavirin.
For de patienter, som fik > 10,6 mg/kg Rebetol (800 mg dosis i en typisk patient på 75 kg), uafhængigt af genotype eller virusmængde, var responsrater signifikant højere end for de patienter, der fik  10,6 mg/kg Rebetol (Tabel 7), mens responsrater for patienter, der fik > 13,2 mg/kg Rebetol, var endnu højere. 
In those patients that received > 10.6 mg/kg Rebetol (800 mg dose in typical 75 kg patient), regardless of genotype or viral load, response rates were significantly higher than in those patients that received  10.6 mg/kg Rebetol (Table 7), while response rates in patients that received > 13.2 mg/kg Rebetol were even higher.
Virologisk respons i uge 4, defineres som et fald på mindst 1-log viral load eller et ikke-detekterbart niveau af HCV-RNA. 
Virological response by week 4 is defined as at least 1-log viral load decrease or undetectable levels of HCV-RNA.
Rebetol-dosis (daglig) 
Rebetol Dose (daily)
De fleste af ændringerne i laboratorieværdierne for de kliniske forsøg med Rebetol/peginterferon alfa-2b var milde eller moderate. 
Most of the changes in laboratory values in the Rebetol/peginterferon alfa-2b clinical trial were mild or moderate.
I denne undergruppe af patienter var der 92 % (89/97) med vedvarende virologisk responsrate. 
In this subgroup, there was a 92 % (89/97) sustained virological response rate.
Anvendelsen af Rebetol i kombination med peginterferon alfa-2b havde ingen observerbar negativ indvirkning på kontrollen af hiv-viræmi under behandling eller opfølgning. 
The use of Rebetol in combination with peginterferon alfa-2b had no observable negative impact on the control of HIV viraemia during therapy or follow-up.
Behandlingsvarigheden var 48-uger med en opfølgningsperiode på 6 måneder med undtagelse af patienter, der var inficeret med genotype 2 eller 3 og viral load < 800.000 IE/ml (Amplicor), som blev behandlet i 24 uger med en 6 måneders opfølgningsperiode. 
The duration of therapy was 48 weeks with a follow-up period of 6 months except for patients infected with genotypes 2 or 3 and viral load < 800,000 IU/mL (Amplicor) who were treated for 24 weeks with a 6 month follow-up period.
Tabel 6 Vedvarende virologisk respons rate (n a,b 
Table 6 Sustained virological response rates (n a,b
Genotoksisk aktivitet sås i mus lymfomtest og ved doser på 20200 mg/kg i en mus mikronucleusprøve. 
Genotoxic activity was observed in the mouse lymphoma assay, and at doses of 20-200 mg/kg in a mouse micronucleus assay.
Tabel 13 Vedvarende virologisk respons rate (n a,b 
Table 13 Sustained virological response rates (n a,b
Brug ikke lægemidlet uden at tale med din læge eller apotekspersonalet, hvis du bemærker en ændring i udseendet af opløsningen. 
Do not use this medicine without advice of your doctor or pharmacist if you notice any change in the appearance of the solution.
Tre undersøgelser vurderede anvendelsen af interferon hos naive patienter, to med Rebetol + interferon alfa-2b (C95-132 og I95-143) og en med Rebetol + peginterferon alfa-2b (C/I98580). 
Three trials examined the use of interferon in naïve patients, two with Rebetol + interferon alfa-2b (C95-132 and I95-143) and one with Rebetol + peginterferon alfa-2b (C/I98-580).
Farmakokinetikken for Rebetol og interferon alfa-2b (dosis-normaliseret) er ens hos voksne og børn eller unge. 
The pharmacokinetics of Rebetol and interferon alfa-2b (dose-normalized) is similar in adults and children or adolescents.
Dosering af Rebetol for børn og unge patienter er baseret på patientens legemsvægt. 
Dosing of Rebetol for children and adolescent patients is determined by the patient body weight.
Rebetol oral opløsning indtages oralt fordelt på to doser (morgen og aften) i forbindelse med et måltid. 
Rebetol oral solution is administered orally in two divided doses (morning and evening) with food.
Hjælpestoffer, som behandleren skal være opmærksom på Rebetol indeholder 142 mg sorbitol og 300 mg saccharose per ml. 
Excipients with known effect Rebetol contains 142 mg of sorbitol and 300 mg of sucrose per mL.
For patienter som tidligere har været behandlet med ikke pegyleret interferon eller pegyleret interferon og som har været negative i 12. behandlingsuge, var den fortsatte responsrate henholdsvis 59 % og 50 %. 
For patients with prior failure on therapy with non-pegylated interferon or pegylated interferon and negative at week 12, the sustained response rates were 59 % and 50 %, respectively.
To store undersøgelser med langtidsopfølgning inkluderede 1.071 patienter og 567 patienter efter behandling i tidligere undersøgelser med henholdsvis non-pegyleret interferon alfa-2b (med eller uden Rebetol) og pegyleret interferon alfa-2b (med eller uden Rebetol). 
Two large long-term follow-up studies enrolled 1,071 patients and 567 patients after treatment in prior studies with non-pegylated interferon alfa-2b (with or without Rebetol) and pegylated interferon alfa-2b (with or without Rebetol), respectively.
Det er muligt, at den mindskede biotilgængelighed i denne undersøgelse skyldtes forsinket overførsel af Rebetol eller ændret pH. 
It is possible that the decreased bioavailability in this study was due to delayed transit of Rebetol or modified pH.
Det skal du vide, før du begynder at bruge Rebetol 
What you need to know before you use Rebetol
Kaplan-Meier estimatet for fortsat vedvarende respons over 5 år er 97 % (95 % CI: 95-99 %) for patienter, der fik non-pegyleret interferon alfa 2b (med eller uden Rebetol), og det er 99 % (95 % CI: 98-100 %) for patienter, der fik pegyleret interferon alfa-2b (med eller uden Rebetol). 
The Kaplan-Meier estimate for continued sustained response over 5 years is 97 % (95 % CI: 95-99 %) for patients receiving non-pegylated interferon alfa-2b (with or without Rebetol), and is 99 % (95 % CI: 98-100 %) for patients receiving pegylated interferon alfa-2b (with or without Rebetol).
Undersøgelsens resultater er sammenfattet i Tabel 13. 
The study results are summarized in Table 13.
Meget sjældne bivirkninger (kan forekomme hos op til 1 ud af 10.000 personer): - selvmord, - slagtilfælde (cerebrovaskulær hændelse). 
Very rarely reported side effects (may affect up to 1 in 10,000 people): suicide, stroke (cerebrovascular events).
Biotilgængeligheden af Rebetol 600 mg blev reduceret ved samtidig indtagelse af et antacidum indeholdende magnesium, aluminium og simeticon; AUCtf faldt 14 %. 
The bioavailability of Rebetol 600 mg was decreased by co-administration with an antacid containing magnesium, aluminium and simethicone; AUCtf decreased 14 %.
Standard hæmatologiske test, blodkemi (komplet blodtælling og differentialtælling, blodpladetal, elektrolytter, serum kreatinin, leverfunktionsundersøgelser, urinsyre) og graviditetstest skal udføres hos alle patienter før påbegyndelse af behandling. 
Standard haematologic tests, blood chemistries (complete blood count [CBC] and differential, platelet count, electrolytes, serum creatinine, liver function tests, uric acid) and pregnancy tests must be conducted in all patients prior to initiating therapy.
Er du i tvivl, så spørg lægen eller apotekspersonalet, før du tager Rebetol. 
If you are not sure, talk to your doctor or pharmacist before taking Rebetol.
Der synes ikke at være farmakokinetisk interaktion mellem Rebetol og leverfunktionen (se pkt. 
No pharmacokinetic interaction appears between Rebetol and hepatic function (see section 5.2).
Navn og adresse på den fremstiller, der er ansvarlig for batchfrigivelse af den orale opløsning 
Name and address of the manufacturer responsible for batch release for the oral solution
KaplanMeier estimatet for fortsat vedvarende respons i 5 år er 98 % [95 % CI: 95 %, 100 %] for pædiatriske patienter behandlet med interferon alfa-2b og ribavirin. 
The Kaplan-Meier estimate for continued sustained response over 5 years is 98 % [95 % CI: 95 %, 100 %] for paediatric patients treated with interferon alfa-2b and ribavirin.
* For patienter, som får en dosis på 1.000 mg (< 75 kg) eller 1.200 mg (> 75 kg), skal Rebetol-dosis reduceres til 600 mg/dag (administreret som en 200 mg kapsel om morgenen og to 200 mg kapsler om aftenen). 
* For patients receiving a 1,000 mg (< 75 kg) or 1,200 mg (> 75 kg) dose, Rebetol dose should be reduced to 600 mg/day (administered as one 200 mg capsule in the morning and two 200 mg capsules in the evening).
I denne undersøgelse var kombinationen af Rebetol og peginterferon alfa-2b (1,5 mikrogram/kg/uge) signifikant mere effektiv end kombinationen af Rebetol og interferon alfa-2b, især hos patienter inficeret med genotype 1. 
In this trial, the combination of Rebetol and peginterferon alfa-2b (1.5 micrograms/kg/week) was significantly more effective than the combination of Rebetol and interferon alfa-2b, particularly in patients infected with Genotype 1.
Rebetols farmakokinetik er ændret hos patienter med nedsat nyrefunktion som følge af en reduktion af den tilsyneladende clearance hos disse patienter. 
The pharmacokinetics of Rebetol is altered in patients with renal dysfunction due to reduction of apparent clearance in these patients.
Vedvarende respons 
Sustained Response
Ved peginterferon alfa-2b 1,5 μg/kg plus Rebetol dosen, var den vedvarende virologiske responsrate lavere hos patienter med cirrose, end patienter med normal ALT-værdi, hos patienter med en baseline viral load > 600.000 IE/ml, og hos patienter > 40 år. 
At the peginterferon alfa-2b 1.5 µg/kg plus Rebetol dose, sustained virologic response rates were lower in patients with cirrhosis, in patients with normal ALT levels, in patients with a baseline viral load > 600,000 IU/mL and in patients > 40 years old.
Derudover fremkaldte ribavirin ikke tumorer i en 26 ugers karcinogenicitetsundersøgelse med den heterozygote p53(+/-) musemodel og den maksimale tolererede dosis på 300 mg/kg (plasma ekspositionsfaktor cirka 2,5 sammenlignet med human eksponering). 
In addition, in a 26 week carcinogenicity study using the heterozygous p53(+/-) mouse model, ribavirin did not produce tumours at the maximally tolerated dose of 300 mg/kg (plasma exposure factor approximately 2.5 compared to human exposure).
EU/1/99/107/001 (84 hårde kapsler) EU/1/99/107/005 (112 hårde kapsler) EU/1/99/107/002 (140 hårde kapsler) EU/1/99/107/003 (168 hårde kapsler) 
EU/1/99/107/001 (84 hard capsules) EU/1/99/107/005 (112 hard capsules) EU/1/99/107/002 (140 hard capsules) EU/1/99/107/003 (168 hard capsules)
Rebetol indeholder saccharose og sorbitol 
Rebetol contains sucrose and sorbitol
Der er ingen tegn på, at Rebetol har interaktion med ikke-nukleosid reverse transcriptasehæmmere eller proteasehæmmere. 
There is no evidence that Rebetol interacts with non-nucleoside reverse transcriptase inhibitors or protease inhibitors.
Baseret på offentliggjorte data var enkeltdosisfarmakokinetikken for ribavirin ændret (øget AUCtf og Cmax) hos patienter med nedsat nyrefunktion sammenlignet med kontrolpersoner (kreatininclearance > 90 ml/minut). 
Based on published data, single-dose ribavirin pharmacokinetics was altered (increased AUCtf and Cmax) in patients with renal dysfunction compared with control subjects (creatinine clearance > 90 mL/minute).
Forudsigelighed med hensyn til vedvarende virologisk respons hos naive patienter Virologisk respons ved uge 12, defineret som et fald på mindst 2-log viral load eller ikke-detekterbart niveau af HCV RNA. 
Predictability of sustained virological response in naïve patients Virological response by week 12 is defined as at least 2-log viral load decrease or undetectable levels of HCV-RNA.
Rebetol indeholder: - Aktivt stof: Ribavirin 200 mg. - Øvrige indholdsstoffer: Mikrokrystallinsk cellulose, lactosemonohydrat (40 mg), croscarmellosenatrium og magnesiumstearat. 
- The active substance is ribavirin 200 mg. - The other ingredients are microcrystalline cellulose, lactose monohydrate (40 mg), croscarmellose sodium, magnesium stearate.
Genotype 2/3/4 (n=26) 
Genotype 1 (n = 92) Genotype 2/3/4 (n = 26)
Der er ingen tegn fra toksicitetsundersøgelser på, at Rebetol inducerer leverenzymer. 
There is no evidence from toxicity studies that Rebetol induces liver enzymes.
Samtidig anvendelse af Rebetol med zidovudin kan ikke anbefales som følge af en øget risiko for anæmi (se pkt. 
The concomitant use of Rebetol with zidovudine is not recommended due to an increased risk of anaemia (see section 4.4).
I individuelle tilfælde, hvor fordelen ved administrationen af Rebetol sammen med azathioprin opvejer den potentielle risiko, anbefales tæt hæmatologisk monitorering ved samtidig brug af azathioprin for at identificere tegn på myelotoksicitet. 
In individual cases where the benefit of administering Rebetol concomitantly with azathioprine warrants the potential risk, it is recommended that close hematologic monitoring be done during concomitant azathioprine use to identify signs of myelotoxicity, at which time treatment with these medicines should be stopped (see section 4.4).
I kliniske undersøgelser C95-132 og I95-143 viste Rebetol + interferon alfa-2b kombinationsbehandling sig at være signifikant mere effektiv end interferon alfa-2b monoterapi (en fordobling i vedvarende respons). 
In clinical trials C95-132 and I95-143, Rebetol + interferon alfa-2b combination therapy proved to be significantly more effective than interferon alfa-2b monotherapy (a doubling in sustained response).
Du eller din kvindelige partner skal bruge sikker prævention i den periode, du tager Rebetol og i 7 måneder efter, behandlingen er stoppet. 
You or your female partner must use an effective contraceptive during the time you are taking Rebetol and for 7 months after stopping treatment.
Patienter, som udvikler leverdekompensation, skal seponere antihepatitis-behandlingen øjeblikkeligt, og ARV-behandlingen skal revurderes. 
Patients progressing to hepatic decompensation should have their anti-hepatitis treatment immediately discontinued and the ARV treatment reassessed.
Et givet antal bivirkninger tilskrevet interferonbehandling, men som har været rapporteret i sammenhæng med hepatitis C-behandling (i kombination med Rebetol) er også listet i Tabel 5. 
A certain number of adverse reactions, generally attributed to interferon therapy but that have been reported in the context of hepatitis C therapy (in combination with Rebetol) are also listed for reference in Table 5.
Interferon alfa-2b 3 MIE/m 2 3 gange om ugen (n = 54) 
Interferon alfa-2b 3 MIU/m 2 3 times a week (n = 54)
Normal daglig Rebetol-dosis 
Usual daily Rebetol dose
Immunsystemet Ikke almindelig: 
Immune system disorders Uncommon:
Rebetol skal altid anvendes i kombinationsbehandling som beskrevet i pkt. 
Rebetol must be used in combination therapy as described in section 4.1.
oral opløsning 1 flaske på 100 ml 10 ml oral doseringssprøjte 
1 bottle of 100 mL 10 mL oral dosing syringe
Vægttab og væksthæmning var meget almindeligt under behandlingen (ved slutningen af behandlingen var gennemsnitlig reduktion fra baseline i vægt- og højdepercentil henholdsvis 15 percentiler og 8 percentiler) og væksthastighed var inhiberet (< 3. percentil i 70 % af patienterne). 
Weight loss and growth inhibition were very common during the treatment (at the end of treatment, mean decrease from baseline in weight and in height percentiles were of 15 percentiles and 8 percentiles, respectively) and growth velocity was inhibited (< 3
Det er muligt, at den øgede biotilgængeligheden i denne undersøgelse skyldtes forsinket overførsel af ribavirin eller ændret pH. 
It is possible that the increased bioavailability in this study was due to delayed transit of ribavirin or modified pH.
Propylenglycol Ammoniumhydroxid Farvestof (E 132) 
Propylene glycol Ammonium hydroxide Colouring agent (E 132)
Hvis HCV-RNA findes positivt i uge 12 og der er et fald på ≥ 2log10 fra baseline, skal der re-testes for HCV-RNA i uge 24, og hvis denne findes positivt, skal patienten stoppe behandlingen. 
If week 12 HCV-RNA is positive and decreased ≥ 2 log10 from baseline, then retest HCV-RNA at week 24 and if positive, patients to stop therapy.
REBETOL - 84, 112, 140, 168 hårde kapsler 
REBETOL - 84, 112, 140, 168 hard capsules
oral opløsning 100 ml 
oral solution 100 mL
Hyperglykæmi, hyperurikæmi, hypokalcæmi, dehydrering, øget appetit 
Hyperglycaemia, hyperuricaemia, hypocalcaemia, dehydration, increased appetite
Positiv anti-tyroid antistof 
Anti-thyroid antibody positive
Kombinationsbehandling med Rebetol + interferon alfa-2b resulterede i et vedvarende virologisk respons, der var ti gange større end ved interferon alfa-2b alene (49 % mod 5 %, p < 0,0001). 
Combination therapy with Rebetol and interferon alfa-2b resulted in a sustained virological response that was ten-fold higher than that with interferon alfa-2b alone (49 % vs 5 %, p < 0.0001).
Hos patienter med afroamerikansk oprindelse (som er kendt for at være en dårlig prognostisk faktor for HCV udryddelse), medførte en behandling med peginterferon alfa-2b (1,5 μg/kg)/Rebetol kombinationsbehandling højere vedvarende virologisk responsrate sammenlignet med peginterferon alfa-2b 1 μg/kg dosis. 
In patients of African American origin (which is known to be a poor prognostic factor for HCV eradication), treatment with peginterferon alfa-2b (1.5 µg/kg)/Rebetol combination therapy resulted in a higher sustained virologic response rate compared to peginterferon alfa-2b 1 µg/kg dose.
Undersøgelsens resultater er summerede i Tabel 7. 
The study results are summarized in Table 7.
Rebetol hæmmer ikke CYP-enzymer. 
Rebetol does not inhibit cytochrome P450 enzymes.
Den inkluderede population bestod hovedsageligt af børn med mild til moderat hepatitis C. I de to multicenterforsøg, vedvarende virologiske responsrater hos børn og unge svarede til dem, der sås hos voksne. 
The population enrolled mainly consisted in children with mild to moderate hepatitis C. In the two multicentre trials, sustained virological response rates in children and adolescents were similar to those in adults.
Depression, søvnløshed, emotionel labilitet 
Depression, insomnia, emotional lability
Naturlig og kunstig tyggegummismag. 
Natural and artificial bubble gum flavouring
Daglig Rebetol-dosis 
Daily Rebetol dose
I kliniske undersøgelser med 118 børn og unge 3 til 16 år, behandlet i kombination med interferon alfa-2b og Rebetol, afbrød 6 % behandling på grund af bivirkninger. 
In clinical trials of 118 children and adolescents 3 to 16 years of age treated with combination therapy of interferon alfa-2b and Rebetol, 6 % discontinued therapy due to adverse reactions.
Dette lægemiddel i kombination med peginterferon alfa-2b eller interferon alfa-2b kan også bevirke: - mørk, grumset eller unormalt farvet urin, - vejrtrækningsproblemer, ændringer i den måde dit hjerte slår, brystsmerte, smerte i venstre arm, 
This medicinein combination with peginterferon alfa-2b or interferon alfa-2b may also cause: dark, cloudy or abnormally coloured urine, difficulty breathing, changes in the way your heart beats, chest pain, pain down left arm, jaw pain,
De farmakokinetiske data for Rebetol (dosis-normaliseret) i dette studie svarede til dem rapporteret i et forudgående studie af Rebetol i kombination med interferon alfa-2b hos børn og unge patienter og hos voksne patienter. 
The pharmacokinetics of Rebetol (dose-normalized) in this trial was similar to those reported in a prior study of Rebetol in combination with interferon alfa-2b in children and adolescent patients and in adult patients.
c: Patienter med genotype 3 lav viral load (< 600,000 IE/ml) skulle modtage 24 ugers behandling mens de med genotype 3 og høj viral load (≥ 600,000 IE/ml) skulle modtage 48 uger behandling. 
c: Patients with genotype 3 low viral load (< 600,000 IU/mL) were to receive 24 weeks of treatment while those with genotype 3 and high viral load (≥ 600,000 IU/mL) were to receive 48 weeks of treatment.
Mitokondriel toksicitet og mælkesyreacidose har været rapporteret hos hiv-positive patienter, der modtog NRTI regimen og associeret Rebetol for samtidig HCV-infektion (se pkt. 
Mitochondrial toxicity and lactic acidosis have been reported in HIV-positive patients receiving NRTI regimen and associated-Rebetol for co-HCV infection (see section 4.4).